These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33598084)

  • 41. CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease.
    Kim HN; Jeon HJ; Choi HG; Kwon IS; Rou WS; Lee JE; Lee TH; Kim SH; Lee BS; Shin KS; Lee HJ; Eun HS
    BMC Gastroenterol; 2023 Mar; 23(1):77. PubMed ID: 36932382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease.
    Hosseini SA; Shayesteh AA; Hashemi SJ; Rahimi Z; Saki N; Bavi Behbahani H; Cheraghian B; Alipour M
    BMC Gastroenterol; 2024 May; 24(1):159. PubMed ID: 38724894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
    Demir M; Deyneli O; Yılmaz Y
    Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
    Yi M; Chen RP; Yang R; Chen H
    Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study.
    Chung SM; Moon JS; Yoon JS; Won KC; Lee HW
    J Trace Elem Med Biol; 2020 Dec; 62():126601. PubMed ID: 32634767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Palmisano L; Masulli M; Cossu E; Baroni MG; Bonomo K; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Aldigeri R; Cas AD; de Kreutzenberg SV; Targher G
    Cardiovasc Diabetol; 2023 Aug; 22(1):204. PubMed ID: 37563618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
    Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
    Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease.
    Sheng G; Lu S; Xie Q; Peng N; Kuang M; Zou Y
    Lipids Health Dis; 2021 Oct; 20(1):134. PubMed ID: 34629059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ankle systolic pressure index in non-diabetic non-alcoholic fatty liver disease: A case-control study.
    Taharboucht S; Guermaz R; Brouri M; Bengherbia L; Chibane A
    J Med Vasc; 2023; 48(5-6):154-162. PubMed ID: 38035921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease.
    Xia MF; Yki-Järvinen H; Bian H; Lin HD; Yan HM; Chang XX; Zhou Y; Gao X
    PLoS One; 2016; 11(8):e0160526. PubMed ID: 27579785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
    Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
    World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India.
    Kamalraj N; Sathishkumar M; Arunvignesh M; Baskar V; Jebarani S; Amutha A; Deepa M; Shanthi Rani CS; Chandru S; Unnikrishnan R; Anjana RM; Harish M; Mohan V
    Diabetes Metab Syndr; 2021; 15(5):102261. PubMed ID: 34464909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study.
    Lee HH; Cho Y; Choi YJ; Huh BW; Lee BW; Kang ES; Park SW; Cha BS; Lee EJ; Lee YH; Huh KB
    Cardiovasc Diabetol; 2020 Jun; 19(1):81. PubMed ID: 32534588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy.
    Chang JW; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Gut Liver; 2021 Jan; 15(1):117-127. PubMed ID: 32066210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.
    Lv WS; Sun RX; Gao YY; Wen JP; Pan RF; Li L; Wang J; Xian YX; Cao CX; Zheng M
    World J Gastroenterol; 2013 May; 19(20):3134-42. PubMed ID: 23716995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).
    Saokaew S; Kanchanasuwan S; Apisarnthanarak P; Charoensak A; Charatcharoenwitthaya P; Phisalprapa P; Chaiyakunapruk N
    Liver Int; 2017 Oct; 37(10):1535-1543. PubMed ID: 28294515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Abdominal Ultrasonography Results of Cappadocia Cohort Study of Turkey Reveals High Prevalence of Fatty Liver.
    Sezgin O; Akpınar H; Özer B; Törüner M; Bal K; Bor S
    Turk J Gastroenterol; 2023 Jun; 34(6):652-664. PubMed ID: 37303246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.